Skip to main content
BioLineRx Ltd. logo

BioLineRx Ltd. — Investor Relations & Filings

Ticker · BLRX ISIN · US09071M2052 LEI · 529900AKIOSC15Y63R18 TA Manufacturing
Open in API
Filings indexed 1,676 across all filing types
Latest filing 2022-11-04 Regulatory Filings
Country IL Israel
Listing TA BLRX

About BioLineRx Ltd.

https://www.biolinerx.com/

BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. The company leverages its drug development capabilities to advance novel, early-stage therapeutic candidates through the clinical development process toward regulatory approval. Its pipeline consists of treatments, including small molecules, designed to address unmet medical needs and deliver meaningful benefits to patients. BioLineRx also partners with other drug developers to advance their early-stage programs.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2022-11-04 English
BioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Multiple Myeloma and Program for Potential Motixafortide Indication Expansion in Gene Therapy at the 64th American Society o
Regulatory Filings Classification · 95% confidence The document is explicitly titled 'FORM 6-K' and is filed with the 'SECURITIES AND EXCHANGE COMMISSION' by a 'FOREIGN PRIVATE ISSUER'. Form 6-K is a general reporting requirement for foreign private issuers, often used to file material information that is required to be made public in the issuer's home country or stock exchange, or that is distributed to shareholders. The content is a press release announcing presentations at the ASH Annual Meeting and providing updates on clinical trials and cost-effectiveness studies for their drug, motixafortide. Since Form 6-K is a catch-all regulatory filing for foreign private issuers that doesn't fit the specific US periodic reports (like 10-K or 10-Q), and the content is a general corporate/clinical update, it falls best under the 'Regulatory Filings' category, which serves as the fallback for miscellaneous filings that do not neatly fit elsewhere, or it could be considered a general regulatory announcement. Given the options, 'RNS' (Regulatory Filings) is the most appropriate classification for a Form 6-K that contains a press release about clinical data and conference presentations, as it is a mandatory regulatory disclosure that doesn't match the specific content codes (like ER, IP, or LTR). However, looking closely at the definitions, RNS is defined as 'General regulatory announcements and fallback category for miscellaneous filings that do not neatly fit into other specific categories.' A Form 6-K is a specific SEC form, but its content here is an announcement of scientific data presentation. Since there is no specific code for 'Clinical Data Announcement' or 'Scientific Update', RNS is the best fit as a general regulatory filing/announcement.
2022-11-03 English
BioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Multiple Myeloma and Program for Potential Motixafortide Indication Expansion in Gene Therapy at the 64th American Society o
Report Publication Announcement Classification · 98% confidence The document is an 'Immediate Report' filed under Regulation 4 of the Securities Regulations, indicating it is a regulatory filing by a foreign corporation. The text explicitly states, 'Attached hereto is a report on *BioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide...*' and references a PDF file. The document itself is very short (2112 characters) and serves primarily to announce the publication of another document (likely a Form 6-K or similar disclosure regarding presentations at a medical meeting). This fits the definition of a Report Publication Announcement (RPA), as it announces the release of information rather than containing the full report content itself. Since RPA is a specific category for announcements of report publication, it is preferred over the general 'RNS' fallback.
2022-11-03 English
6-K
Regulatory Filings
2022-11-03 English
BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization
Regulatory Filings Classification · 98% confidence The document is explicitly titled 'FORM 6-K' and is filed with the 'SECURITIES AND EXCHANGE COMMISSION'. Form 6-K is the standard filing used by Foreign Private Issuers to report material information that is made public in their home country or required to be filed with a foreign securities exchange. This type of filing is generally used for current reports that do not fit neatly into the periodic reporting requirements of Form 20-F (Annual Report). Since the provided definitions do not have a specific code for Form 6-K, and this document contains a press release announcing a commercialization plan and NDA submission, it functions as a general regulatory disclosure. The closest fit among the provided options for a non-periodic, general regulatory disclosure from a foreign issuer, especially when the content is a press release about business updates, is 'Regulatory Filings' (RNS), as it serves as a catch-all for required SEC submissions that aren't 10-K, IR, or ER. However, given the structure (a cover page for a specific SEC form), it is a formal regulatory filing. If we must choose from the list, RNS is the most appropriate fallback for a Form 6-K that isn't an earnings release (ER) or a specific report type. The content itself is a press release announcing commercialization plans and NDA submission, which is material information.
2022-09-27 English
BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization
Report Publication Announcement Classification · 98% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority and the Tel Aviv Stock Exchange, referencing a Form 6-K filing (a common SEC filing for foreign private issuers). The core content states: 'Attached hereto is a report on*BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization* *Form_6-K_27-Sep-22_isa.pdf*'. Since the document itself is short (1938 chars) and serves primarily to announce the publication of an attached/linked report (the Form 6-K PDF), it fits the definition of a Report Publication Announcement (RPA). It is not the full financial report (10-K or IR) nor a general regulatory filing (RNS), as RPA is more specific for announcing the release of other documents.
2022-09-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.